Theraworx Relief Joint Discomfort And Inflammation

Dosage for Frankincense varies significantly based on the indication and the concentration of the standardized extract being used.

• For Allergy Testing: The dosage is standardized by the manufacturer of the patch test (e.g., T.R.U.E. Test). A small amount of the extract is pre-loaded onto a patch and applied to the patient's back for 48 hours.
• For Osteoarthritis: The typical adult dosage ranges from 300 mg to 500 mg of a standardized extract (containing 60-65% boswellic acids) taken two to three times daily. Some high-potency extracts (e.g., 5-Loxin or Aflapin) may require lower doses, such as 100 mg once daily.
• For Inflammatory Bowel Disease: Clinical studies have utilized doses of 350 mg to 400 mg three times daily for up to 6 weeks to assess initial response.
• For Asthma: A common dosage used in research is 300 mg three times daily.

Frankincense is not currently approved by the FDA for therapeutic use in children. There is insufficient safety data to establish a standard pediatric dose. Use in children should only occur under the direct supervision of a specialist, such as a pediatric allergist or rheumatologist. For allergy testing, the use of patch tests in children is determined by the clinician based on the child's skin surface area and the severity of their symptoms.

Renal Impairment

Specific dosage adjustments for patients with kidney disease have not been established. However, because a small portion of metabolites are excreted renally, caution is advised in patients with Stage 4 or 5 Chronic Kidney Disease (CKD). Monitoring for systemic accumulation is recommended.

Hepatic Impairment

Since Frankincense is primarily metabolized by the liver (CYP3A4), patients with hepatic impairment (Child-Pugh Class B or C) may experience increased plasma concentrations. A dose reduction of 50% may be considered, along with frequent monitoring of liver function tests (LFTs).

Elderly Patients

No specific age-related dose adjustments are required for geriatric patients. However, clinicians should consider the higher prevalence of polypharmacy (taking multiple medications) in the elderly, which increases the risk of drug-drug interactions.

To ensure maximum efficacy and safety, patients should adhere to the following instructions:

1. 1Take with Food: Frankincense (Boswellia) should always be taken with a meal, preferably one containing healthy fats (such as avocado, olive oil, or dairy). This can increase the absorption of active boswellic acids by over 300%.
2. 2Swallow Whole: If taking capsules or tablets, swallow them whole with a full glass of water. Do not crush or chew standardized extract tablets unless specifically instructed, as this may alter the release profile.
3. 3Consistency: Take the medication at the same times each day to maintain steady-state plasma levels.
4. 4Storage: Store Frankincense products in a cool, dry place (between 59°F and 86°F / 15°C and 30°C). Keep the container tightly closed and away from direct sunlight and moisture, which can degrade the resin components.

If you miss a dose, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to make up for a missed one, as this increases the risk of gastrointestinal side effects.

Signs of an acute overdose of Frankincense may include:

• Severe nausea and vomiting
• Intense abdominal pain or cramping
• Diarrhea
• Skin rash or hives (urticaria)
• Dizziness or lethargy

In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. Treatment is generally supportive, focusing on gastric lavage and fluid replacement if severe vomiting or diarrhea occurs.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop taking Frankincense without medical guidance, especially if using it to manage chronic inflammatory conditions.

Frankincense is generally well-tolerated when used at recommended dosages, but some patients may experience mild to moderate side effects. The most common issues involve the digestive system:

• Gastrointestinal Distress: This includes a feeling of fullness, bloating, or mild stomach cramps. This typically occurs shortly after ingestion and may diminish as the body adjusts to the supplement.
• Acid Reflux (Heartburn): Some patients report a burning sensation in the chest or throat, particularly if the supplement is taken on an empty stomach.
• Nausea: A feeling of queasiness that is usually transient and can be mitigated by taking the dose with a large meal.
• Dermatological Reaction (Patch Test): When used as a diagnostic allergen, redness and itching at the site of the patch are expected in sensitive individuals; this is the intended diagnostic response.

• Diarrhea: Loose or frequent stools may occur, particularly with higher doses (above 1000 mg per day).
• Headache: Some patients report mild tension-type headaches during the first week of use.
• Dizziness: A slight feeling of lightheadedness or vertigo has been reported in a small percentage of clinical trial participants.
• Skin Rash: Non-specific pruritus (itching) or a mild maculopapular rash may develop on areas of the body away from the application site.

• Hepatotoxicity: Rare cases of elevated liver enzymes have been noted. This is usually reversible upon discontinuation of the drug.
• Hypersensitivity Pneumonitis: Extremely rare reports of lung inflammation have occurred following the inhalation of frankincense smoke or dust in industrial settings.
• Menstrual Changes: Because Frankincense may act as an emmenagogue (a substance that stimulates blood flow in the pelvic area), some women may experience heavier or irregular menstrual bleeding.

> Warning: Stop taking Frankincense and call your doctor immediately if you experience any of the following serious symptoms:

• Anaphylaxis: Signs include difficulty breathing, swelling of the face, lips, or tongue, severe hives, and a rapid or weak pulse. This is a life-threatening allergic emergency.
• Severe Abdominal Pain: Sharp, localized pain that could indicate a more serious gastrointestinal issue or gallbladder irritation.
• Jaundice: Yellowing of the skin or the whites of the eyes, which may indicate liver dysfunction.
• Easy Bruising or Bleeding: Unexplained nosebleeds, bleeding gums, or large bruises may suggest an interaction with the body's blood-clotting mechanisms.
• Severe Skin Reactions: Blistering, peeling, or a widespread painful rash (such as Stevens-Johnson Syndrome, though this has not been definitively linked to Frankincense, any severe skin reaction requires assessment).

Data on the long-term use (greater than 12 months) of Frankincense is limited. Potential concerns with prolonged exposure include:

• Chronic Gastritis: Persistent irritation of the stomach lining.
• Immune System Modulation: Because Frankincense affects leukotriene synthesis and NF-κB, there is a theoretical concern that long-term use could alter the body's normal immune surveillance, although this has not been clinically proven.
• Tolerance: There is no evidence currently suggesting that patients develop a pharmacological tolerance to the anti-inflammatory effects of boswellic acids.

No FDA black box warnings for Frankincense. As a Standardized Chemical Allergen and botanical extract, it does not currently carry the highest level of FDA warning. However, this does not imply that the substance is without risk; it should be used strictly according to professional guidance.

Report any unusual symptoms or persistent side effects to your healthcare provider. You may also report side effects to the FDA at 1-800-FDA-1088.

Frankincense (Boswellia) must be used with caution, particularly in patients with pre-existing medical conditions or those taking multiple medications. While often perceived as a "natural" remedy, the active boswellic acids are potent pharmacological agents that can significantly alter physiological processes. Patients should be aware that botanical products are not subject to the same rigorous pre-market testing as synthetic pharmaceuticals, making it vital to use standardized products from reputable sources.

No FDA black box warnings for Frankincense.

• Allergic Reactions / Anaphylaxis Risk: Patients with a known allergy to other resins (such as pine resin or balsam of Peru) are at a significantly higher risk of cross-sensitivity. A severe allergic reaction can occur upon first exposure or after repeated use.
• Autoimmune Disease: Because Frankincense can stimulate certain aspects of the immune system while inhibiting others, patients with autoimmune conditions (e.g., Multiple Sclerosis, Lupus, Rheumatoid Arthritis) should use it with extreme caution. It may potentially interfere with immunosuppressive therapies.
• Surgery: Frankincense may have mild anti-platelet effects. It is recommended to discontinue use at least 2 weeks prior to any scheduled surgery to reduce the risk of excessive bleeding during or after the procedure.
• Gastrointestinal Disorders: Patients with a history of peptic ulcer disease or inflammatory bowel disease should be monitored closely, as the resin can occasionally irritate the gastric mucosa despite its anti-inflammatory properties.
• Hepatotoxicity: Although rare, patients with pre-existing liver disease should have their liver enzymes monitored regularly while taking high doses of Boswellia extracts.

If you are taking Frankincense long-term for a chronic condition, your healthcare provider may require the following tests:

• Liver Function Tests (LFTs): To ensure the liver is processing the extract safely.
• Complete Blood Count (CBC): To monitor for any changes in white blood cell counts or platelet activity.
• Clinical Assessment: Regular evaluation of the condition being treated (e.g., joint range of motion for arthritis) to determine if the treatment remains effective.

Frankincense is not generally known to cause sedation or cognitive impairment. However, if you experience dizziness or lightheadedness as a side effect, you should avoid driving or operating heavy machinery until you know how the substance affects you.

There is no direct contraindication between Frankincense and moderate alcohol consumption. However, both alcohol and Frankincense can irritate the stomach lining. Combining them may increase the risk of gastritis or acid reflux. Furthermore, alcohol can strain the liver, potentially compounding the rare risk of hepatotoxicity associated with high-dose Boswellia use.

There are no known withdrawal symptoms associated with stopping Frankincense. However, if you are using it to manage a chronic inflammatory condition, stopping the medication abruptly may cause a "rebound" flare-up of your symptoms (e.g., increased joint pain or asthma symptoms). It is often best to taper the dose over one to two weeks under medical supervision.

> Important: Discuss all your medical conditions, including any history of asthma, stomach ulcers, or liver disease, with your healthcare provider before starting Frankincense.

While there are no absolute contraindications listed by the FDA for Frankincense as an allergen, the following combinations should be avoided in therapeutic contexts:

• Potent CYP3A4 Inducers (e.g., Rifampin, St. John's Wort): These substances can drastically reduce the plasma concentration of boswellic acids, rendering the Frankincense extract ineffective.
• Specific Immunosuppressants (e.g., Cyclosporine): There is a high risk of pharmacodynamic antagonism, where Frankincense may stimulate the immune system and counteract the intended effect of the immunosuppressant, potentially leading to organ transplant rejection or flares in autoimmune disease.

• Anticoagulants and Antiplatelets (e.g., Warfarin, Clopidogrel, Aspirin): Frankincense may have mild blood-thinning properties. Combining it with these drugs increases the risk of bruising and internal bleeding. Patients on Warfarin should have their INR monitored more frequently if starting or stopping Frankincense.
• NSAIDs (e.g., Ibuprofen, Naproxen, Celecoxib): Both NSAIDs and Frankincense affect inflammatory pathways. While they are sometimes used together, the combination may increase the risk of gastrointestinal irritation and ulceration.

• Cytochrome P450 3A4 Substrates (e.g., Simvastatin, Alprazolam, Fentanyl): Frankincense may inhibit the CYP3A4 enzyme. This can lead to increased levels of these drugs in the bloodstream, raising the risk of toxicity and side effects.
• Antidiabetic Medications: Some evidence suggests Frankincense may lower blood sugar levels. When taken with insulin or oral hypoglycemics (like Metformin), it may increase the risk of hypoglycemia (low blood sugar).

• High-Fat Meals: As previously noted, dietary fat significantly increases the absorption of Frankincense. While this is generally beneficial for efficacy, patients should be consistent with their fat intake to avoid fluctuating drug levels.
• Grapefruit Juice: Like Frankincense, grapefruit juice inhibits CYP3A4. Combining the two may lead to unpredictably high levels of both the Frankincense components and other co-administered medications.

• Curcumin (Turmeric): Often sold in combination with Frankincense. While they work synergistically for inflammation, the combination also increases the potential for anti-platelet effects and GI upset.
• Glucosamine/Chondroitin: No significant negative interactions, often used together for joint health.
• Garlic, Ginkgo Biloba, and Vitamin E: These supplements also have blood-thinning properties and should be used cautiously with Frankincense.

• Liver Function Tests: Frankincense may cause a transient rise in ALT, AST, or Bilirubin levels.
• Coagulation Profiles: May slightly prolong Prothrombin Time (PT) or International Normalized Ratio (INR) in sensitive individuals.
• Urine Tests: Components of the resin may cause false positives in certain specialized urine toxicology screens for specific terpenes, though this is rare.

For each major interaction, the mechanism typically involves CYP450 enzyme inhibition or additive pharmacodynamic effects on the blood clotting or immune systems. Management usually involves dose timing adjustments or increased clinical monitoring.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including those purchased over-the-counter.

Frankincense must NEVER be used in the following circumstances:

• Known Hypersensitivity: Patients with a documented allergy to Boswellia serrata, Boswellia carterii, or any other member of the Burseraceae family should avoid all forms of Frankincense. Exposure could lead to anaphylaxis.
• Pregnancy (Therapeutic Doses): Frankincense is considered an emmenagogue and a potential abortifacient. It may stimulate blood flow to the uterus and induce menstruation, which poses a significant risk of miscarriage or preterm labor.
• Active Peptic Ulcer Disease: Due to the potential for gastric irritation, patients with active bleeding ulcers should avoid oral Frankincense preparations as it may exacerbate the condition.

Conditions requiring a careful risk-benefit analysis by a physician include:

• Severe Hepatic Impairment: Because the liver is the primary site of metabolism, patients with end-stage liver disease may not be able to clear the drug, leading to systemic toxicity.
• Bleeding Disorders: Patients with hemophilia or other coagulopathies should use Frankincense only under strict hematological supervision due to its potential anti-platelet effects.
• Scheduled Surgery: As noted, the risk of perioperative bleeding necessitates stopping the drug 14 days prior to any invasive procedure.
• Autoimmune Disorders: The potential for immune stimulation requires a specialist's oversight to ensure the patient's primary treatment is not compromised.

There is a known risk of cross-sensitivity between Frankincense and other botanical resins. Patients who react to Balsam of Peru, Pine Resin (Colophony), or Myrrh should be tested cautiously, as they are more likely to have a Type IV hypersensitivity reaction to Frankincense. This is particularly relevant in the context of diagnostic patch testing, where the clinician must be prepared for a potentially vigorous skin reaction.

> Important: Your healthcare provider will evaluate your complete medical history, including any previous allergic reactions to fragrances or botanical extracts, before prescribing or recommending Frankincense.

FDA Pregnancy Category: Not Assigned (Commonly regarded as Category C or Avoid).

There are no well-controlled studies of Frankincense in pregnant women. However, traditional use and animal data suggest that Frankincense possesses emmenagogue properties, meaning it can stimulate uterine blood flow and potentially trigger contractions. Because of the risk of pregnancy loss, Frankincense is generally contraindicated during pregnancy, especially in the first and second trimesters. If exposure occurs, the patient should consult their obstetrician immediately. Its use in fertility treatments is not supported by clinical evidence.

It is not known whether the active components of Frankincense (boswellic acids) are excreted in human milk. Due to the lack of safety data and the potential for the infant to develop a sensitivity or experience gastrointestinal upset, the use of Frankincense while breastfeeding is generally discouraged. Healthcare providers should perform a risk-benefit analysis, considering the mother's need for the medication versus the potential risks to the nursing infant.

Frankincense is not approved for therapeutic use in children under the age of 18. While it is used in diagnostic patch testing for children with chronic dermatitis, the safety of oral Boswellia extracts in developing children has not been established. There is a theoretical concern regarding its effects on the developing immune system. Growth effects have not been studied.

Clinical trials for osteoarthritis often include a significant number of elderly participants, and Frankincense appears to be safe in this population. However, geriatric patients are at an increased risk for:

• Polypharmacy: Interactions with blood thinners, blood pressure medications, and diabetes drugs are more common.
• Reduced Renal/Hepatic Clearance: Natural age-related declines in organ function may lead to higher drug concentrations.
• Fall Risk: If dizziness occurs as a side effect, it may increase the risk of falls in the elderly.

There are no specific guidelines for Frankincense use in patients with renal impairment. However, clinicians should monitor the glomerular filtration rate (GFR) if high doses are used long-term. Frankincense is not known to be cleared by hemodialysis; therefore, supplemental doses after dialysis are likely unnecessary.

In patients with hepatic impairment, the metabolism of boswellic acids is likely delayed. For patients with Child-Pugh Class A (mild) impairment, no adjustment may be needed, but for Class B and C (moderate to severe), the drug should be used with extreme caution or avoided entirely. Monitoring for signs of hepatic encephalopathy or worsening jaundice is essential.

> Important: Special populations require individualized medical assessment. Always inform your specialist if you are pregnant, planning to become pregnant, or have underlying organ dysfunction.

Frankincense (Boswellia) acts as a non-redox, non-competitive inhibitor of the enzyme 5-lipoxygenase (5-LOX). 5-LOX is the key enzyme responsible for transforming arachidonic acid into leukotrienes (LTB4, LTC4, LTD4, LTE4). These leukotrienes are powerful mediators of inflammation, bronchoconstriction, and vascular permeability. By specifically targeting 5-LOX, Frankincense provides an anti-inflammatory effect that is distinct from NSAIDs, which target the cyclooxygenase (COX) pathway.

Additionally, the compound 3-O-acetyl-11-keto-β-boswellic acid (AKBA) has been shown to inhibit Nuclear Factor-kappa B (NF-κB) activation. This prevents the expression of various pro-inflammatory cytokines, such as Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 beta (IL-1β), and Interleukin-6 (IL-6). This dual action on both the leukotriene and cytokine pathways makes it a potent botanical modifier of the inflammatory response.

• Dose-Response: Therapeutic effects on joint pain and stiffness are typically dose-dependent, with higher concentrations of AKBA yielding faster results.
• Onset of Action: Unlike acute analgesics, the anti-inflammatory effects of Frankincense are not immediate. Patients typically report significant improvement in symptoms after 2 to 4 weeks of consistent use.
• Duration of Effect: The biological effects of 5-LOX inhibition may persist for several hours beyond the plasma half-life of the drug due to the tight binding of AKBA to the enzyme.

| Parameter | Value |

|---|---|

| Bioavailability | Low (Highly improved with fat) |

| Protein Binding | >95% (Primarily Albumin) |

| Half-life | 4 - 6 hours |

| Tmax | 2 - 4 hours |

| Metabolism | Hepatic (CYP3A4) |

| Excretion | Fecal (>95%), Renal (<1%) |

• Molecular Formula (AKBA): C32H48O5
• Molecular Weight: 512.7 g/mol
• Solubility: Highly soluble in organic solvents (lipophilic); poorly soluble in water.
• Structure: A pentacyclic triterpene resin acid. It consists of five fused carbon rings with various functional groups that determine its binding affinity to the 5-LOX enzyme.

Frankincense is classified as a Standardized Chemical Allergen [EPC] for diagnostic purposes. In a therapeutic context, it is considered a 5-Lipoxygenase Inhibitor and a Botanical Anti-inflammatory Agent. It is related to other resins like Myrrh and Guggul, though its specific inhibition of 5-LOX is unique among these substances.